



# **Multiple Sclerosis (MS)**

**ANGELO ANTONINI**



# Introduction to Multiple Sclerosis (MS)

---


- Chronic autoimmune disease
- Progressive disease
- Involves Immune System & Neurological System
- Multifocal areas of demyelination
- Disrupts ability of the nerve to conduct electrical impulses
- Leads to symptoms



# Epidemiology of MS

- Age onset 20 – 50 years old
- Women are 2 times more likely to develop MS
- 500,000 cases in US
- Over 2.5 million people around the world
- More prevalent whites of northern European ancestry
- 110/100.000 occurrence
- Vitamin D3
- Genetic Influences

# World Distribution of Multiple Sclerosis




# Topics


- What is MS
- Who gets MS
- Symptoms
- Types of MS
- Common Questions

# What is MS?


- Demyelination of the Central Nervous System




# MRI patterns












A




B







C



D











Cerebrospinal fluid drawn  
from between two vertebrae




# Oligoclonal Bands in CSF









## Activation Of Brain-Reactive T-Cells Non-Specific Vs. Molecular Mimicry



## Migration Of Inflammatory Cells Into CNS




## Immune Mechanism In Demyelination



## Mechanisms of Demyelination Phagocytosis Vs. Apoptosis



# Pathology in MS



# Symptoms of MS

- Vision problems
- Numbness
- Difficulty walking
- Fatigue
- Depression
- Emotional changes
- Vertigo & dizziness
- Sexual dysfunction
- Coordination problems
- Balance problems
- Pain
- Changes in cognitive function
- Bowel/bladder dysfunction
- Spasticity

# FATIGUE IN MS

- Most common symptom of MS-MS Society estimates that 90% are affected
- Patients rate fatigue as overwhelming and having the biggest impact on their quality of life with 75% saying it is their most bothersome symptom and completely out of proportion to their activity level and can make even the simplest tasks impossible.
- DEFINITION: Extreme tiredness, typically resulting from mental or physical exertion or illness. Ask each of us to describe and we will define differently. Everyone experiences fatigue but persons with MS experience it profoundly.
- *You know you've got brain fog when ... I'm sorry, what were we talking about?*

# FATIGUE IN MS

- Consortium of MS Centers and National MS Society defines as :a subjective loss of physical or mental energy that is perceived by the individual or caregiver to interfere with usual or desired activities.
- Three types: 1. Lassitude (overwhelming feeling of being tired) 2. Muscle fatigue (legs feel too heavy to move) 3. Mental fatigue (too tired to think or concentrate.

# FATIGUE IN MS

- It occurs daily.
- It may be present in the morning, even after a good night's sleep. Sleep restores energy levels in the neurotypical person, not so in MS!!
- It worsens as the day progresses.
- Heat and humidity aggravate it.
- It comes on suddenly.
- It's more severe than normal fatigue and more likely to interfere with daily life and one's ability to cope and carry out their family/work responsibilities.
- Not only physical but mental fatigue-brain fog!
- Often not recognized or overlooked by health care professionals.

# FATIGUE IN MS

- CAUSES:
- PRIMARY:
  - 1. Damage to Central Nervous system causes the CNS to work harder.
  - 2. May be related to decreased functioning or "hypometabolism".
- SECONDARY:
  - 1. Other health conditions: thyroid disorders, diabetes, infections, heart disease etc.



# FATIGUE IN MS

2. Side effects of medications: Interferons, medication for spasticity, pain, anxiety etc
  3. Heat intolerance: saps energy
  4. Depression: chicken and egg dilemma
  5. Over exertion: must pace oneself. "Spoon Theory".
- *You know you've got chronic fatigue syndrome when you wake up in the morning to get ready for your nap.*

# FATIGUE IN MS

What helps?

- 1.** Get proper rest: Establish regular routines, avoid caffeine, alcohol, drinking before bedtime. Seek help for depression, anxiety, financial worries, bladder problems
- 2.** Avoid heat: Get assistance for air conditioners, cooling vests. Swim, take cool showers.
- 3.** Aerobic exercise

# Symptoms

- Sensory



# Impaired Vision

- Optic Neuritis



# Muscle function

- Weakness
- Spasticity
- Foot Drop



# Bowel and Bladder

- Urinary Urgency and Frequency
- Constipation



# Sexual Dysfunction

- Fatigue
- Decreased sensation
- Decreased Libido

Kelly, *Sexuality Today: The Human Perspective*, 6e. Copyright © 1998, The McGraw-Hill Companies, Inc. All Rights Reserved.

## Vicious Cycle of Sexual Dysfunction



# Cognitive Function

- Short term Memory
- Multitasking
- Mood





# Cognitive dysfunction in MS

- Discussed by Charcot 1877
- Difficult to study
  - population differences
  - clinical tools insensitive
  - neuropsychological tests expensive/unavailable
  - difficult to recognize by physicians/patients



## My Early thoughts :

- 1 Occurs late in disease
- 2 Occurs after substantial disability
- 3 Not present in CIS



# 3 types of memory - 1

- **Sensory memory** - retention for less than **1/2 second**; degraded quickly
- **Short-term memory** - allows recall for a period of **several seconds to a minute** ; typically approx. 4-5 items
  - dependent dorsolateral **prefrontal cortex and parietal lobe**. The **hippocampus /limbic circuit** is essential for learning new information
  - storage *short-term memory* have a strictly limited capacity and duration
- **Working memory**: temporary storage and manipulation of information required for complex tasks.

## 3 types of memory - 2

- **long-term memory** - stores large quantities of information for potentially unlimited duration
  - enhanced with repetition
- requires stable permanent neural connections widely throughout the brain.
- The hippocampus and limbic circuit is essential for consolidation from short-term to long-term memory

# Cognitive dysfunction in MS

## Epidemiology:

- MS clinics 53 – 65%
- Community 43 – 48%
- Increases over 10 yrs 26-56%

*adapted from Amato MP et al J Neurol Sci 2006; 245(1-2):41-6  
Arch Neurol 2001; 58(10):1602-6*

- COGIMUS- community volunteers study ~35%
- MACFIMS- consecutive clinic attendees ~60%
- Little data on natural history over time but does not remit and may worsen at variable rate

Kujala et al 1997

# Predictors of cognitive dysfunction

- Correlation :

poor - with clinical indicators relapses or disability

- good - with MRI burden of disease ( 83% of patients with  $> 30 \text{ cm}^2$  lesion area were cognitively impaired)
- 22% if  $< 30 \text{ cm}^2$  -Rao et al, 1989)

- neuropathological substrate

- Studies tend to show impairment more severe with progressive disease ; but .....bias precludes conclusion on subtype relevance
- Signs of cognitive deterioration at onset of MS

# MRI in Cognitive assessment

- Modest MRI correlation.....
  - lesion volume scores esp. left frontal lobe
- Stronger MRI correlation .....
- global and regional cerebral atrophy :
  - third ventricle size
  - corpus callosum size
  - ventricular-brain ratios
  - neocortical grey volume loss (Amato et al Arch Neurol 2007;64(8):1157-61)

# Cognitive Dysfunction: Domains Most Commonly Affected

(Rao et al, 1991)

- Short term memory
- Attention
- Concentration
- Verbal intelligence
- Visuospatial skills
- Information processing
- Less: language, long term memory

# Cognitive domains affected in MS

- Slowed information processing (bradyphrenia)- most common deficit ; It may mirror EDDS status, but other deficits may not
- Impaired recent memory
  - “episodic ” ( visual and verbal) information that is seen, read, or heard
  - working
- Impaired retrieval
- Impaired visuospatial function
- Simple attention and verbal ability intact



Multi-tasking is a problem



# Cognitive domain deficits in MS-

## Memory dysfunction

*adapted from Amato MP et al J Neurol Sci  
2006; 245(1-2):41-6*

### Attention and concentration deficits

- “alternating attention” (shifting between two stimuli)
- “divided attention” (simultaneous attention to multiple stimuli)

**Impaired executive functions**  
such as concept formation,  
reasoning, problem-solving,  
planning and sequencing ,  
abstraction



# Risk factors for cognitive dysfunction:

adapted Benedict RHB, Zivadinov R Nat. Rev. Neurol. 2011 ;7 :332-42

- Early age of onset ( data from pediatric neurology)
- Male sex
- Depression, fatigue, duration of disease poorly or not correlated (seen early or in CIS)
- Transition from RRMS to SPMS

# Risk factors for cognitive dysfunction:

adapted Benedict RHB, Zivadinov R Nat. Rev. Neurol. 2011 ;7 :332-42

- **Life style/behaviour**
  - Tobacco- Smoking is a MS susceptibility risk factor; associated with progression
  - Cannabis- (Small studies +ve) -? ??
- **Genetic factors – No association**
  - HLA-DR 15 (MS susceptibility risk factor)
  - APOE4



# Risk factors for cognitive dysfunction:

Julian L Neurol Clin 2011 ; 20: 507-25

- **Depression/(anxiety)**
  - independent risk factor(evidence from longitudinal studies)
  - affects attention & concentration, processing speed and impacts executive function in MS
  - both may occur for same neuropathological damage
  - cognitive impairment predicts poor response to antidepressants

# Consequences of Cognitive impairment in functional domains

More likely to be :

- prone to psychiatric morbidity
- unemployed,
- socially withdrawn
- difficulty performing routine household tasks

Rao SM Neurology 1991;41(5):692–6.

- Affects several functional domains:  
social , occupational, educational , capacity for decision making (medical), driving, use of public transport, cooking

Chiaravalloti ND Lancet Neurol 2008;7(12):1139–51



# Cognitive dysfunction in MS conclusions

- Occurs in approx. 50% patients with consequence
- Cognitive domains most affected are *mental processing speed* and *episodic memory*
- Specific Neuropsychological test are sensitive but not widely available to clinicians
- Risks factors include:
  - males of low education or intelligence
  - early onset of MS
  - evidence of cerebral grey matter atrophy
- Evidence for effect of any medical therapy inconsistent

adapted Benedict RHB, Zivadinov R Nat. Rev. Neurol. 2011 ;7 :332-42


# Types of MS

---

- Relapsing-remitting MS (RRMS)
  - Affects 85% of newly diagnosed
  - Attacks followed by partial or complete recovery
  - Symptoms may be inactive for months or years
- Secondary-progressive MS (SPMS)
  - Occasional relapses but symptoms remain constant, no remission
  - Progressive disability late in disease course

# Types of MS


- Relapsing Remitting





# Types of MS

- Secondary Progressive




# Types of MS

- Primary-progressive MS (PPMS)
  - Affects approximately 10% of MS population
  - Slow onset but continuous worsening condition
- Progressive-relapsing MS (PRMS)
  - Rarest form
  - Affects approx. 5%
  - Steady worsening of condition at onset

# Types of MS

- Primary Progressive






# Classification

- Stable
- Relapse
- Progression

Click on graphs 1-4 for a description.

D  
I  
S  
A  
B  
I  
L  
I  
T  
Y



T I M E →

# Other Factors Influencing MS

- **Vitamin D deficiency**
  - Vitamin D3 receptor important in immune function
  - Present on T regulator cells
- **Infectious Mono/EBV**
  - 99% of MS patients have EBV titers
  - Usually higher than in HC
  - Pseudo follicles in meninges containing B cells showing ENA antigen
  - EBER RNA found in inflammatory lesions
  - Protein stimulates Toll 3 receptors which release proinflammatory interferons
  - In inflammatory lesions T cells found surrounding B cells containing ENA antigen
- **Genetics**
  - HLA DRB2 \*1503 allele 2x risk factor
  - IL 2 receptor
  - IL 7 receptor
  - 50 new candidates genes each with low risk factors

# Vitamin D

---

- Vitamin D is a lipophilic vitamin synthesized by the conversion of 7 dehydrocholesterol to Vitamin D in the skin by ultraviolet radiation from the sun usually.

# Role of Vitamin D in MS

## Background Information

1. US cohort study found that 3.5 times more women residing in northern states were diagnosed with MS than southern states
2. Incidence of MS highest in North Temporal Climate
3. MS more prominent in areas reporting less than 2000 hours of sunshine annually
4. MS displays seasonable variability with increased activity in the Spring and lowest in the Fall.
5. A Finnish study found in MS patients lower serum vitamin D levels in the Spring.
6. A line between dietary intake of vitamin D and the incidence of MS has been suggested in Norway along the coastal areas where fatty fish, dairy products, and cereals are all rich in vitamin D consumed in higher amounts. The incidence is lower than the rest of Norway.
7. Dietary information from the Nurse's Health Study of 187,000 women showed those with a history of vitamin D supplementation as low as 400 units daily had a 40% less chance of developing MS.
8. Levels of 1, 25 hydroxy D<sub>3</sub> and 1

# Diseases to rule out

- Viral infections
- Lyme disease
- B12 deficiency
- CVA
- Lupus
- Rheumatoid arthritis
- Other connective tissue disorders
- Vasculitis
- Syphilis
- Tuberculosis
- HIV
- Sarcoidosis



# Medications and MS

<b>Therapies</b>	<b>Administration</b>	<b>CLASS</b>
<b>Avonex</b>	<b>IM 1x a week</b>	<b>Interferon beta-1a</b>
<b>Betaseron</b>	<b>SC, every other day</b>	<b>Interferon beta-1b</b>
<b>Copaxone</b>	<b>SC 1x a day</b>	<b>Glatiramer acetate</b>
<b>Rebif</b>	<b>SC 3x a week</b>	<b>Interferon beta-1a</b>
<b>Gilenya</b>	<b>Oral capsule 1x day</b>	<b>Fingolimod</b>
<b>Tysabri</b>	<b>IV Monthly at Center</b>	<b>Natalizumab</b>

# Side effects of MS medication

- Local injection site irritation/reactions
- Flu like symptoms
- Rise in liver enzymes
- Decreased white cell count and platelets
- Opportunistic infections
- Depression
- Progressive multifocal leukoencephalopathy (PML)

# Fatigue

- Medications
  - Amantadine
  - Ritalin drugs
  - Focalin
  - Adderall
  - Provigil/Nuvigil

# Depression

- Selective Serotonin Reuptake Inhibitors
  - Paxil
  - Prozac
  - Zoloft
  - Lexapro
  - Celexa
- Tricyclic Antidepressants
  - Elavil
  - Pamelor
  - Tofranil
  - Norpramin
- Some other medications
  - Desyrel
  - Serzone
  - Welbutrin
  - Effexor
- Referral for counseling
- Psychologist
- Encourage expression of feelings will entire team and caregivers
- Work on solution together

# Bladder problems

- Rule out UTI
- Bladder training
  - Strengthen pelvic muscles
- Medication
- Anti-spasticity
  - Vesicare
  - Detrol
  - Ditropan
- Referral to urologist for further evaluation and treatment

# Sexual Dysfunction

---

- Medications
  - Viagra
  - Cialis
  - Levitra

# Constipation

- Increase oral intake
- Increase fiber intake
- Miralax
- Metamucil
- Citrucel
- Colace



“In those four out of five doctors commercials, I’m the fifth doctor.”



# RIS (Radio logically Isolated Syndrome)

- White matter lesions suggestive of demyelinating disease on MRI
- Normal neuro exam
- No medical history compatible with MS
- Unclear whether RIS is subclinical MS or a separated entity
- About 33% of subjects with RIS develop a CIS especially with spinal cord lesions

# Cortical Lesions

- Present on autopsy and biopsy studies
- Sometimes quite extensive
- Cause of cognitive dysfunction
- Amount of brain volume loss has been shown to be associated with cognitive impairment
- Inflammation not seen in chronic MS lesions in the cortex
- Luchinetti has shown cortical perivenular inflammation in acute lesion using cortical biopsy but response last only days, however.

# MRI – Double Inversion Recovery (DIR)

- WM & CSF signals suppressed
- 3D DIR increases intracortical lesion detection by 500% compared to standard T2 spin echo and by more than 150% compared to FLAIR
- Post mortem brain slice lesion detection by using DIR & FLAIR & pathological exam
- DIR showed 35/198 total lesion i.e.: 18% detection (1.6 >FLAIR)
- Showed pathological specificity for 3D DIR was 90% & FLAIR 81%
- 9 more intracortical lesion seen by DIR but most missed by both techniques especially subpial and intracortical ones.

# Treatment Options

- Non FDA approved
  - a) Cellcept
  - b) Cytoxan
  - c) Laquinomod
  - d) Cladribine
  - e) Fumarate (BG12)
  - f) Terflunomide
  - g) Monoclonal antibodies
    1. Alemtuzimab (Campath)
    2. Rituximab
    3. Dacluzimab
    4. Anti Lingo antibody
  - h) Vaccines
    - a) Tovaxin